This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 7 for:    IPH2201
Previous Study | Return to List | Next Study

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Innate Pharma
Information provided by (Responsible Party):
Canadian Cancer Trials Group
ClinicalTrials.gov Identifier:
NCT02459301
First received: May 19, 2015
Last updated: April 20, 2017
Last verified: March 2017
  Purpose
The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.

Condition Intervention Phase
Gynecologic Cancer Drug: IPH2201 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

Further study details as provided by Canadian Cancer Trials Group:

Primary Outcome Measures:
  • Dose of single agent IPH2201 for phase II studies and determined based on toxicity, as well as pharmacokinetic and pharmacodynamics data [ Time Frame: 24 months ]
    To confirm the recommended phase II dose (RP2D) of single agent IPH2201 in patients with advanced/metastatic/recurrent platinum sensitive or resistant high-grade serous carcinoma (HGSC) of ovarian, fallopian tube or peritoneal origin.


Secondary Outcome Measures:
  • Number and severity of adverse events in patients [ Time Frame: 24 months ]
    • Safety and tolerability of IPH2201

  • Correlative assays evaluation for potential predictive markers of IPH2201 effects. Concentration at the end of administration (Cinf end) for all patients [ Time Frame: 24 months ]
    Correlative assays will be used to evaluate potential predictive markers of IPH2201 effects. Other potential prognostic or predictive molecular factors will be assesses in archival tumour tissue, CTCs and blood samples.

  • Area under the curve from time 0 to Tau=2 weeks (AUC(0-Tau) [ Time Frame: 24 months ]
  • Accumulation ratio, in terms of Cmax and AUC(0-Tau), between C1 and C4 [ Time Frame: 24 months ]

Enrollment: 59
Actual Study Start Date: August 24, 2015
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IPH2201

Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks.

Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1

Drug: IPH2201

Detailed Description:

This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy may cause this cancer to shrink for a time, better options are needed. In laboratory tests and animals, IPH2201 has been shown to have effects which result in shrinkage of tumours. IPH2201 has been studied in people with rheumatoid arthritis but it has not yet been studied in people with cancer and the investigators do not know if it can offer better results than standard treatment.

The standard or usual treatment for this disease could include surgery, chemotherapy or radiation.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a histologically and/or cytologically confirmed gynecologic malignancy including high-grade serous ovarian/fallopian tube or peritoneal carcinoma, cervical cancer (squamous cell carcinoma) or endometrial cancer (adenocarcinoma), that is advanced/metastatic/recurrent or unresectable and for which no curative therapy exists.
  • For patients with HGSC: For Part 2 of this study, patients will be classified as either platinum resistant or platinum sensitive, as defined by their previous response to platinum-based therapy:

    • The platinum resistant cohort will include patients with disease progression within 6 months of the last line of platinum-based therapy dose.
    • The platinum sensitive cohort will be defined by progression 6 months or longer since last platinum-based therapy dose.
  • All patients must have an available formalin fixed paraffin embedded tissue block (from their primary or metastatic tumour) and must have provided informed consent for the release of the block (or slides), as well as for samples for correlative studies and banking.

    • At least 4 patients registered to each cohort in Part 2 must also have provided informed consent for and be willing to undergo a tumour biopsy prior to treatment (after registration) and after treatment with IPH2201. Note: During accrual to Part 2, it may be necessary to restrict accrual to patients who are suitable for, and have consented to, tumour biopsy before and after treatment.

  • Presence of clinically and/or radiologically documented disease. All radiology studies must be performed within 28 days prior to randomization/registration (within 35 days if negative).

All patients must have measurable disease as defined by RECIST 1.1. The criteria for defining measurable disease are as follows:

Chest x-ray ≥ 20 mm CT scan (with slice thickness of 5 mm) ≥ 10 mm --> longest diameter Physical exam (using calipers) ≥ 10 mm Lymph nodes by CT scan ≥ 15 mm --> measured in short axis

  • Patients must be ≥ 18 years of age.
  • Patients must have an ECOG performance status of 0, 1, or 2.
  • Previous Therapy
  • Cytotoxic Chemotherapy: All patients must have received at least one prior regimen of chemotherapy for advanced, metastatic, or recurrent disease, one of which must have been platinum-based. Patients may have received no more than 3 prior regimens.
  • Other systemic therapy: All patients may have received other therapies including immunotherapy, angiogenesis inhibitors, PARP inhibitors or signal transduction inhibitors.
  • Patients must have recovered from all reversible toxicity related to prior chemotherapy or systemic therapy and have adequate washout as follows:

Longest of one of the following:

  • Two weeks
  • 5 half lives for investigational agents
  • Standard cycle length of standard therapies

    • Radiation: Prior external beam radiation is permitted provided a minimum of 28 days (4 weeks) have elapsed between the last dose of radiation and date of randomization/registration. Exceptions may be made for low-dose, non-myelosuppressive radiotherapy after consultation with NCIC CTG.
    • Surgery: Previous surgery is permitted provided that a minimum of 28 days (4 weeks) have elapsed between any major surgery and date of randomization/registration, and that wound healing has occurred.

Patients must have recovered from any treatment related toxicities prior to randomization/registration (unless grade 1, irreversible, or considered by investigator as not clinically significant).

  • Absolute neutrophils ≥ 1.5 x 10^9/L
  • Platelets ≥ 100 x 10^9/L
  • Bilirubin ≤ 1.5 x ULN (upper limit of normal)
  • AST and ALT ≤ 2.5 x ULN
  • Serum creatinine < 1.25 x ULN ; ≤ 5.0 x UNL if patient has known liver metastases
  • Women of childbearing potential must have agreed to use a highly effective contraceptive method during the study and for up to 5 months after the last dose of IPH2201.
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to randomization/registration in the trial and prior to tests which are considered to be study specific to document their willingness to participate.
  • Patients who cannot give informed consent (i.e. mentally incompetent patients, or those physically incapacitated such as comatose patients) are not to be recruited into the study. Patients competent but physically unable to sign the consent form may have the document signed by their nearest relative or legal guardian. Each patient will be provided with a full explanation of the study before consent is requested.
  • Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial. Investigators must assure themselves the patients registered on this trial will be available for complete documentation of the treatment, response assessment, adverse events, and follow-up.
  • In accordance with CCTG policy, protocol treatment is to begin within 5 working days of patient randomization (Part 1) or registration (Part 2).

Exclusion Criteria:

  • Patients with a history of other active or current malignancies that require active treatment.
  • Patients with serious illness or medical conditions that might be aggravated by treatment or limit compliance including, but not limited to:

    • History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
    • Uncontrolled diabetes
    • Active uncontrolled or serious infection (viral, bacterial or fungal)
    • Other medical conditions that might be aggravated by study treatment
  • Patients with active immune-mediated diseases or known HIV infection or hepatitis B or C.
  • Patients receiving systemic corticosteroid therapy at doses equivalent to more than 5 mg prednisone. Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are permitted.
  • Patients receiving cytokines and/or growth factors.
  • Patients who have experienced severe adverse effects from other immunotherapy-based treatment or monoclonal antibodies.
  • Patients receiving concurrent treatment with other anti-cancer therapy or investigational agents.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02459301

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada, V1Y 5L3
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
London Regional Cancer Program
London, Ontario, Canada, N6A 5W9
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
CHUM - Hopital Notre-Dame
Montreal, Quebec, Canada, H2L 4M1
Sponsors and Collaborators
Canadian Cancer Trials Group
Innate Pharma
Investigators
Study Chair: Hal Hirte Juravinski Cancer Centre at Hamilton Health Sciences, ON Canada
Study Chair: Anna Tinker BCCA - Vancouver Cancer Centre, BC Canada
  More Information

Responsible Party: Canadian Cancer Trials Group
ClinicalTrials.gov Identifier: NCT02459301     History of Changes
Other Study ID Numbers: I221
Study First Received: May 19, 2015
Last Updated: April 20, 2017

ClinicalTrials.gov processed this record on September 25, 2017